Enveric Biosciences (ENVB) announced that its subsidiary, Akos Biosciences, has licensed to Totec Pharma its U.S. Trademark portfolio for Rcann and an Rcann design. Totec, an affiliate of Aries Science & Technology, is advancing the commercialization of patented cannabinoid creme technology created by Enveric and intended for use in treatment of radiation dermatitis. The trademark license to Totec includes an option to purchase the Rcann trademark portfolio in the future, contingent on Totec meeting certain development and commercialization milestones.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric Biosciences Raises Capital Through Equity Offering
- Enveric to sell 328,802 shares at $4.41 in registered direct offering
- Enveric Biosciences Releases Updated Investor Presentation Materials
- Enveric Biosciences announces issuance of U.S. patent
- Enveric Biosciences files to sell 882,627 shares of common stock for holders